Study on Gene Expression Characteristics in Skin Areas Suspected of Having Solar Lentigines or Melasma

Study on Gene Expression Characteristics in Skin Areas Suspected of Having Solar Lentigines or Melasma - Gene Expression Analysis Study of Skin Areas Suspected of Solar Lentigines or Melasma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059491

Enrollment

100

Registered

2025-10-21

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solar Lentigines, Melasma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with pigmentation spots (such as spots or melasma) at ALOOP CLINIC & LAB, operated by the General Incorporated Association Astronauts Individuals who have received an explanation of this study, fully understood its contents, and voluntarily agreed to participate by providing informed consent Healthy individuals aged 18 years or older Individuals capable of completing, entering, or electronically signing consent forms and related documents

Exclusion criteria

Exclusion criteria: Individuals with a history of severe hepatic disorder, renal disorder, or myocardial infarction Individuals with severe anemia Individuals with a keloid predisposition (those whose scars tend to become raised and red, resembling a worm-like swelling, and heal poorly) Individuals with diabetes mellitus Individuals taking medications that affect skin sampling, such as antiplatelet agents (e.g., aspirin) or anticoagulants Individuals with bleeding or hemostatic disorders Individuals with a history of serious blood-borne infections, such as HIV, hepatitis B, hepatitis C, or syphilis Individuals who have traveled within the past 14 days to areas where infectious diseases are prevalent (as designated by the Ministry of Foreign Affairs' Infectious Disease Risk Information) Individuals with cold symptoms or a fever of 37.5C or higher Any other individuals deemed inappropriate for participation by the principal investigator of the research institution

Design outcomes

Primary

Measure	Time frame
Comprehensive Gene Expression Analysis of Pigmented and Normal Skin Areas	—

Secondary

Measure	Time frame
Correlation Analysis Between Questionnaire Data and Information Obtained During Clinical Examinations at Research Institutions (Including Skin Information, Facial Images, and Measured Numerical Data) and Comprehensive Gene Expression Analysis Results	—

Countries

Japan

Contacts

Public ContactTaku Nishijo

POLA Chemical Industries, Inc. Frontier Research Center

t-nishijo@pola.co.jp045-826-7232

Outcome results